Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
1996-09-09
2002-10-29
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
C424S773000, C424S774000, C424S779000
Reexamination Certificate
active
06471997
ABSTRACT:
BACKGROUND OF THE INVENTION
TECHNICAL FIELD OF THE INVENTION
The subject of the present invention, in its most general aspect, is an extract of cells of at least one plant of the Iridaceae family, the said plant being obtained by in vitro culture. The subject of the invention is also compositions containing an extract of cells of at least one plant of the Iridaceae family, the use of the said extracts as antagonists of CGRP and/or of substance P and a process of cosmetic treatment involving one of the said compositions.
To the knowledge of the applicant, up until now, no extract of cells of at least one plant of the Iridaceae family has been described, the said plant being obtained by in vitro culture.
The applicant having demonstrated, after long studies, specific properties of such an extract, it proposes, as novel product, an extract of cells of at least one plant of the Iridaceae family, the said plant being obtained by in vitro culture.
In the text which follows, the term “Iridaceae cells” should be understood as “cells of at least one plant of the Iridaceae family.” Likewise, the term “Iridaceae extract” should be understood as “extract of Iridaceae cells” and therefore as “extract of cells of at least one plant of the Iridaceae family.”
The extract of cells of at least one plant of the Iridaceae family may be an extract prepared from any plant material derived from the Iridaceae family, the said material having been obtained by in vitro culture.
The selection pressure imposed by the physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain a plant material which is standardized and available throughout the year, contrary to the plants obtained by in vitro culture.
In vitro culture is understood to mean the range of techniques known to a person skilled in the art which makes it possible artificially to obtain a plant or a portion of a plant.
Thus, for example, according to the invention, the extract may be an extract of an organ or even of cells of an organ of at least one Iridaceae obtained by in vitro culture (root, stem, leaf) or alternatively an extract of undifferentiated cells of at least one Iridaceae.
Preferably, an extract obtained from undifferentiated cells obtained by in vitro culture is used.
Undifferentiated plant cells is understood to mean any plant cell exhibiting none of the characters of a specific specialization and capable of living by itself and not in dependence on other cells. These undifferentiated plant cells may be capable, under the effect of an induction, of any differentiation consistent with their genome.
According to the chosen method of culture, and in particular according to the chosen culture medium, it is possible to obtain, from the same explant, undifferentiated plant cells having different characters.
The Iridaceae (or Irid) family comprises about 750 species.
The plants of the Iridaceae family are used especially for their aromatic and ornamental properties.
Among the Iridaceae genera which can be used according to the invention, there may be mentioned by way of example the genera Romulea, Crocus, Iris, Gladiolus, Sisyrinchium or alternatively Hermodactylus.
As plant material which can be used, there may be mentioned that obtained from
Iris germanica, Iris florentina, Iris pallida, Crocus versicolor, Romulea bulbucodium
or alternatively
Gladiolus Communis.
More particularly, according to the invention, plant material derived from the genus Iris, more particularly from
Iris pallida
, is used.
Any method of extraction known to persons skilled in the art may be used according to the invention.
There may be mentioned in particular alcoholic, especially ethanolic, extracts and aqueous-alcoholic extracts.
There may also be used an extract prepared by the method described in French Patent Application No. 95-02379.
Thus, in a first step, the plant material is ground in an aqueous solution at cold temperature, in a second step, the particles in suspension are removed from the aqueous solution derived from the first step, and in a third step, the aqueous solution derived from the second step is sterilized. This aqueous solution corresponds to the extract.
Moreover, the first step may be advantageously replaced by a simple operation of freezing the plant tissues (for example at −20° C.), followed by an aqueous extraction comprising the second and third steps described above.
An example of extract preparation which can be used according to the invention is given, furthermore, in the examples.
The subject of the invention is also a cosmetic or pharmaceutical composition comprising, as active ingredient, in a cosmetically or pharmaceutically acceptable medium, at least one extract of plant material of at least one Iridaceae as defined above.
Active ingredient is understood to mean any molecule or extract capable of modifying or modulating the function of at least one given biological system.
There are, in mammals, polypeptides belonging to the family of tachykinins which induce rapid contractions on the smooth muscle fibres. Among the compounds of this family, there may be mentioned b-neurokinin, a-neurokinin and substance P.
Substance P is a polypeptide chemical component (undecapeptide), produced and released by a nerve ending. The location of substance P is specific to the neurons, both in the central nervous system and in the organs at the periphery. Thus, numerous organs or tissues receive afferences of substance P-bearing neurons; these are especially the salivary glands, the stomach, the pancreas, the intestine (in the latter, the distribution of substance P is superposed on the intrinsic Meissner's and Auerbach's nerve plexus), the cardiovascular system, the thyroid gland, the skin, the iris and the ciliary bodies, the bladder and obviously the central and peripheral nervous systems.
By virtue of the ubiquitous distribution of substance P, numerous disorders are associated with an excessive synthesis and/or release of substance P.
Substance P is involved especially in the transmission of pain and in diseases of the central nervous system (for example anxiety, psychoses, neuropathies, neurodegenerative disorders of the type comprising senile dementia of Alzheimer, dementia of AIDs sufferers, Parkinson's disease, Down's syndrome, Korsakoff's syndrome, multiple sclerosis, schizophrenia), in respiratory diseases (such as for example bronchopneumonia) and inflammatory diseases (such as for example rheumatoid arthritis), in allergic syndromes (such as for example asthma, allergic rhinitis, allergic pharyngitis, urticaria, eczematous dermatitis), in gastrointestinal diseases (such as for example ulcers, colitis, Crohn's disease), in skin disorders (such as for example psoriasis, pruriginous diseases, herpes, photodermatosis, atopic dermatitis, contact dermatitis, lichen, prurigo, pruritus, erythema, in particular solar erythema, insect bites), in fibrosis and other collagen maturation disorders (such as for example scleroderma), in cardiovascular disorders, vasospastic disorders (such as for example migraine, Reynaud's disease), in immunological disorders, in disorders of the urinary tract (such as for example incontinence, cystitis), in rheumatic diseases, in some dermatological diseases (such as eczema) and in ophthalmological conditions (such as for example conjunctivitis, uveitis, ocular pruritus, ocular pain, irritations).
The use of a substance P antagonist is one of the therapeutic alternatives which are effective in all the abovementioned conditions.
Substance P antagonist is understood to mean any compound capable of inhibiting partially, or even completely, the biological effect of substance P.
In particular, for a substance to be recognized as a substance P antagonist, it should induce a coherent pharmacological response (including or otherwise its attachment to the substance P receptor) especially in one of the following tests:
the antagonist substance should reduce the extravasation of plasma across the vascular wall induced by capsaicin or by an
Breton Lionel
De Lacharriere Olivier
Martin Richard
Burns Doane Swecker & Mathis L.L.P.
Societe L'Oreal S.A.
Wilson James O.
LandOfFree
Iridaceae extract and compositions containing it does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Iridaceae extract and compositions containing it, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iridaceae extract and compositions containing it will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2998457